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ABSTRACT
Aim: to analyze the effect of metformin on ammonia pro-
duction derived from glutamine metabolism in vitro and 
in vivo. 
Methods: twenty male Wistar rats were studied for 28 days 
after a porto-caval anastomosis (n = 16) or a sham operation 
(n = 4). Porto-caval shunted animals were randomized into 
two groups (n = 8) and either received 30 mg/kg/day of 
metformin for two weeks or were control animals. Plasma 
ammonia concentration, Gls gene expression and K-type 
glutaminase activity were measured in the small intestine, 
muscle and kidney. Furthermore, Caco2 were grown in dif-
ferent culture media containing glucose/glutamine as the 
main carbon source and exposed to different concentra-
tions of the drug. The expression of genes implicated in 
glutamine metabolism were analyzed. 
Results: metformin was associated with a significant inhi-
bition of glutaminase activity levels in the small intestine 
of porto-caval shunted rats (0.277 ± 0.07 IU/mg vs 0.142 ± 
0.04 IU/mg) and a significant decrease in plasma ammonia 
(204.3 ± 24.4 µg/dl vs 129.6 ± 16.1 µg/dl). Glucose with-
drawal induced the expression of the glutamine transporter 
SLC1A5 (2.54 ± 0.33 fold change; p < 0.05). Metformin use 
reduced MYC levels in Caco2 and consequently, SLC1A5 
and GLS expression, with a greater effect in cells dependent 
on glutaminolytic metabolism. 
Conclusion: metformin regulates ammonia homeostasis by 
modulating glutamine metabolism in the enterocyte, exert-
ing an indirect control of both the uptake and degradation 
of glutamine. This entails a reduction in the production of 
metabolites and energy through this pathway and indirectly 
causes a decrease in ammonia production that could be 
related to a decreased risk of HE development.
Key words: Hepatic encephalopathy. Metformin. Ammonia. 
Glutaminase. Glutamine. Cirrhosis. ASCT2. mTOR. Porto-ca-
val anastomosis.
INTRODUCTION
Hepatic encephalopathy (HE) is a common entity caused by 
liver failure that results from acute and chronic disorders 
such as hepatitis and cirrhosis and is one of the main com-
plications of cirrhosis (1). This syndrome involves neuro-
psychiatric dysfunction ranging from subtle psychological 
abnormalities to profound coma due to a metabolic distur-
bance (2). Clinical studies strongly suggest a major role of 
ammonia in the development of brain disturbances in liver 
disease and systemic hyperammonemia is commonly found 
in patients with cirrhosis and HE (3). The pathophysiological 
mechanisms include alteration of blood-brain-barrier per-
meability, cytokine production, changes in neurotransmitter 
synthesis and release, neuronal oxidative stress, impaired 
mitochondrial function and osmotic disturbances resulting 
from astrocytic metabolism (4).
Ammonia is mainly produced in the small intestine during 
protein digestion and nitrogen metabolism carried out 
by epithelial cells and bacterial flora (5). The majority of 
the gut ammonia is a by-product derived from glutamine 
metabolism into glutamate and ammonia by the enzyme 
glutaminase (EC 3.5.1.2) (4). In a damaged liver, especial-
ly a cirrhotic one which can have up to four times more 
ammonia producing activity, hepatocytes cannot han-
dle the overload and urea cycle is saturated (6). Neural 
amino acid transporter B(0) (ATB[0] or ASCT2 encoded 
by SLC1A5) is a glutamine transporter that also plays an 
important role in metabolism and amino acid homeosta-
sis of cells in most tissues and it may be relevant in glu-
tamine-derived ammonia production (7). Both proteins 
(ASCT2 and glutaminase) are critical for glutaminolytic 
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metabolism, which in turn is regulated by the MYC pro-
to-oncogene, a master regulator of metabolism (8). One 
of the most important signaling functions of ASCT2 is the 
link with the mammalian target of the rapamycin (mTOR) 
pathway. This integrates signals from five major routes, 
including growth factors, cellular stress, energy status, 
oxygen and amino acids (9). In fact, it is thought that gluta-
mine metabolism could sustain cell energy requirements 
and be essential for growth and viability when regulated 
rapid cell division is required. This is important in pro-
cesses such as wound healing (i.e., liver regeneration), 
immune responses to specific antigens or even cancer 
(10). Furthermore, stress and hyperammonemia could rap-
idly increase the ratio a-ketoglutarate/citrate, triggering 
enhanced glutaminolysis and sensitizing the cells to the 
action of several agents (11).
Almost 95% of cirrhotic patients may be glucose intolerant 
and type 2 diabetes mellitus was found in a third of cases 
(12). Furthermore, the association of diabetes and insulin 
resistance in HE risk and cirrhosis progression has been 
previously demonstrated. These diseases have been relat-
ed to enhanced cytokine production and an inflammatory 
state, an increased ammonia production via a glutaminase 
activity increase and constipation (13-15). Metformin is a 
widely used antihyperglycemic drug that has demonstrated 
pleiotropic effects and has also been reported to reduce 
the chronic inflammatory response by inhibiting TNFα pro-
duction (16-17). It also blocks endogenous reactive oxy-
gen species production by interfering with mitochondrial 
complex I activity (18). Ampuero et al. (2012) demonstrated 
in a retrospective study that metformin-exposed cirrhotic 
patients had an eight-fold lower HE risk (19). Furthermore, 
they also demonstrated an in vitro glutaminase activity 
reduction followed by an ammonia production decrease 
after metformin treatment. 
The aim of this study was to analyze the effect of metformin 
on glutaminase (GLS) gene expression and K-type gluta-
minase (KGA) enzyme activity in a rat model of HE and to 
determine the impact of the drug on glutamine metabolism. 
MATERIAL AND METHODS
Experimental design
In vivo study 
All animals used in the study were maintained before, 
during and after experiment according to the directive 
2010/63/EU regarding the use of animals for experimen-
tation and other scientific purposes (Royal Decree-Law 
53/2013, of February 8, laying down basic rules for the pro-
tection of animals used for experimental and other scientific 
purposes, including teaching). All animal procedures were 
performed with the approval of the University of Seville 
Animal Ethics Committee. All experiments were conducted 
on the premises of Service Production and Animal Experi-
mentation of the Institute of Biomedicine of Seville/HUVR 
(registered and authorized center no. ES410910008015). All 
guidelines and regulations concerning the housing condi-
tions of animal experimentation were fulfilled. Appropriate 
measures were taken to minimize the pain or discomfort 
of animals. 
Twenty male Wistar rats with a body weight of 400 ± 24 g were 
individually housed in standard conditions (12 h/12 h light/
dark cycle at 23 ± 2 °C, 50% humidity) with ad libitum access to 
food and water. These animals underwent a sham operation (n 
= 4) or porto-caval shunt (PCS) (n = 16) following the method 
proposed by Numata (20). Two weeks after surgery, operat-
ed rats were randomized into two groups; PCS as a control 
group (n = 8) and PCS + Met (n = 8). The latter group received 
30 mg/kg/day of metformin (Acofarma, Madrid, Spain) with 
the food during the experimental period of 14 days. Animals 
were sacrificed by exsanguination and blood was withdrawn 
from the descending aorta and immediately put into ice cold 
EDTA tubes, centrifuged at 3,000 rpm at 4 °C, and plasma was 
collected. Muscle, kidneys and small intestine (scrapings of 
intestinal villi) were collected and washed in cold phosphate 
saline buffer. Approximately 100 mg of tissue were processed 
for enzymatic activity as described below. The remaining tis-
sue was stored at -80 °C until RNA extraction.
In vitro study
The human colonic epithelial cell line Caco2 was maintained 
in DMEM Low Glucose (w/glucose, w/o glutamine and w/
sodium pyruvate) or DMEM (w/o glucose, w/glutamine and 
w/o sodium pyruvate), supplemented with 100 ml/l fetal 
bovine serum, 100 U/ml penicillin, 100 µg/ml streptomy-
cin, non-essential amino acids and 2 mmol/l L-Glutamine 
(ThermoFisher, MA, USA) in 50 ml/l CO2 at 37 °C. Cell con-
centration was determined with a Neubauer chamber. Cell 
assays were initiated 24 hours after seeding. Caco2 (10,000 
cells/cm2) were cultured in the presence of 2, 5 and 10 mM 
of metformin, based on the work of Javeshghani et al. (21). 
An aliquot of supernatant was collected for every group 24 
hours after initiation of the experiment. After 48 hours, cells 
were collected and stored at -80 °C until assayed.
Gene expression
Total RNA was extracted from cell culture or tissue homog-
enization using TRIzol (22). Reverse transcription reactions 
were performed using the QuantiTect Reverse Transcription 
Kit (Qiagen, Hilden, Germany) according to the manufactur-
er’s protocol. Gene expression was analyzed by quantitative 
polymerase chain reaction (qPCR) using the SensiFAST™ 
SYBR® Lo-ROX Kit (Bioline, MA, USA) and the Illumina Eco 
Real-Time PCR System (Illumina, CA, USA). Nucleic acid con-
centration was measured in a Qubit 2.0 Fluorometer using 
kits for the specific measurement of RNA and DNA (Qubit® 
dsDNA HS Assay Kit, Qubit® RNA HS Assay Kit) (ThermoFish-
er, MA, USA). Glyceraldehyde 3-phosphate dehydrogenase 
(Gapdh) was used as a housekeeping gene in rat and ribo-
somal RNA 18S (RNA18S5) in Caco2. Gene expression levels 
of GLS, MYC proto-oncogene (MYC), mTOR, SLC1A5 and Gls 
were determined by the Delta Ct method, assuming a high 
efficiency of the reaction. Fold change was calculated as the 
sample/control ratio in three independent experiments and 
values were expressed as the mean ± SEM.
Biochemical measurements
Ammonia was measured in cell culture supernatant and in 
rat plasma immediately after collection following the gluta-
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mate-dehydrogenase enzymatic assay in a COBAS Integra® 
700 (ROCHE, Switzerland). 
Enzyme activity
Tissue samples from the small intestine (ileum and duo-
denum), muscle and kidney were homogenized within two 
hours after sacrifice using homogenization buffer (sucrose 
320 mM, Trizma-HCl 10 mM, PMSF 0.2 µM, EDTA 1 mM, 
pH 7.4) (Sigma-Aldrich®, MO, USA) before centrifugation at 
12,000 rpm for 10 min at 4 °C. The mitochondrial-enriched 
pellet was then suspended in incubation buffer (sucrose 70 
mM, EGTA 1 mM, mannitol 210 mM, K2HPO4 150 mM, pH 
8) (Sigma-Aldrich®, MO, USA) and exposed to an ultrasonic 
cell disruptor to ensure the rupture of all cell and mitochon-
drial membranes and the release of free glutaminase from 
the mitochondria. Protein concentration was measured 
using the Bradford method (23).
Glutaminase activity assays were performed following the 
colorimetric protocol described by Heini et al. (24). Specific 
activity of the enzyme was expressed in international units 
(IU) per milligram of total homogenate of protein. One IU 
was defined as a micromole of substrate transformed per 
minute. 
Statistical analysis
Continuous variables are described as the mean and the 
error of a minimum of three independent experiments. 
Data were compared using the ANOVA test with the 
Tukey’s test as post-hoc multiple comparison analyses. 
The Student’s t-test for unpaired samples was used for 
comparisons between two groups. p values p < 0.05 (*) 
and p < 0.01 (**) were considered as statistically signifi-
cant. The SPSS (version 21.0; SPSS, Inc., IL, USA) statis-
tical package was used in all analyses and graphs were 
generated using GraphPad PRISM (version 6.0, GraphPad 
Software, Inc, CA, USA).
RESULTS
Metformin and ammonia production
In PCS rats, metformin treatment for two weeks signifi-
cantly reduced ammonia levels in plasma. Sham-operated 
rats had a mean of 110.8 ± 16.1 µg/dl of plasma ammonia. 
These levels were increased in the PCS-animal model (p = 
0.025) and significantly decreased after metformin treat-
ment (204.3 ± 24.4 µg/dl vs 129.6 ± 16.1 µg/dl; p = 0.038), 
reaching levels similar to sham animals (Fig. 1A).
In the in vitro model after 24 hours of incubation, a dose-de-
pendent decrease in the production of ammonia was found 
in the groups treated with 2, 5 and 10 mM of metformin in 
comparison to the control (Fig. 1B).
Glutaminase expression and activity
As shown in figure 2, no changes in Gls gene expres-
sion levels were associated with PCS or metformin use 
in rats (Fig. 2A). However, PCS induced an increase in 
KGA activity in peripheral tissues such as kidney (0.153 
± 0.05 IU/mg vs 0.337 ± 0.08 IU/mg) and muscle (0.015 ± 
0.005 IU/mg vs 0.086 ± 0.026 IU/mg; p < 0.05) compared 
to sham operation (Fig. 2B). In addition, a reduction in 
KGA activity was observed after metformin treatment in 
the small intestine (0.277 ± 0.07 IU/mg vs 0.142 ± 0.04 
IU/mg) and muscle (0.086 ± 0.026 IU/mg vs 0.054 ± 0.002 
IU/mg), but not in kidney (0.337 ± 0.08 IU/mg vs 0.286 ± 
0.08 IU/mg) (Fig. 2B). However, these data did not reach 
statistical significance.
Fig. 1. Ammonia concentrations in plasma of PCS rats and cell culture. A. Plasma ammonia levels in sham rats (n = 4), 
PCS (n = 8) or PCS + metformin (30 mg/kg/day) (n = 8) expressed as μg/dl; *p < 0.05. Outlier trimming (exclusion) at 
the 5th and 95th percentile was performed for every group in the analysis. B. The percentage of ammonia concentration 
in the culture media of Caco2 exposed to 2, 5 and 10 mM of metformin compared with non-treated cells in three 
independent replicates. Differences between groups were assessed by ANOVA (dashed line) with Tukey’s post-hoc test 
(continuous line); *p < 0.05. Data are expressed as means ± SEM. 
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Metformin and glutamine metabolism in vitro
Despite the fact that ammonia was measured at 2, 5 and 
10 mM, we chose 2 and 5 mM for gene expression level 
analysis based on the results obtained in the proliferation 
MTT assay (data not shown). Treatment with 5 mM met-
formin for 48 hours produced a slight downregulation both 
in mTOR and SLC1A5 expression in Caco2 with access to 
glucose and glutamine (0.49 ± 0.03 and 0.59 ± 0.01 fold 
change respectively; p < 0.05). However, no significant 
changes were found for the other genes analyzed, neither 
at 5 mM nor 2 mM doses (Fig. 3A).
As shown in figure 3B, the absence of glucose in the medi-
um induced the expression of SLC1A5 in comparison to 
cells with free access to both glucose and glutamine (2.54 
± 0.33 fold change; p < 0.05) (Fig. 3B). In the context of 
glucose deprivation, metformin treatment induced changes 
in the expression levels of mTOR and MYC in a dose-de-
pendent manner (0.43 ± 0.24 and 0.58 ± 0.20 fold change, 
at 2 mM [p = ns] and 0.30 ± 0.05 and 0.51 ± 0.03 at 5 mM 
[p < 0.01], respectively). In the same way, GLS and SLC1A5 
expression were downregulated after treatment (0.88 ± 0.13 
[p = ns] and 0.49 ± 0.03 [p < 0.05] fold change respectively 
at 2 mM; 0.28 ± 0.01 and 0.22 ± 0.01 at 5 mM [p < 0.01]) 
(Fig. 3C).
DISCUSSION
In this proof-of-concept study, we investigated the mod-
ulation of ammonia production in the small intestine by 
analyzing glutaminase expression and activity in an animal 
model of hepatic encephalopathy. The effect of metformin 
Fig. 2. Changes in gene expression and activity of K-type 
glutaminase in different tissues. A. Gls mRNA expression 
levels in PCS rats (n = 8) and PCS + metformin (30 mg/
kg/day) (n = 8) expressed as fold change compared with 
the sham group (n = 4) in the small intestine, kidney and 
muscle. B. KGA activity levels expressed as IU/mg. Data 
are the mean value ± SEM and the differences between 
groups were assessed by ANOVA with Tukey’s post-hoc 
test; *p < 0.05.
Fig. 3. Changes in gene expression in Caco2. A. Gene 
expression levels of candidate genes involved in 
glutamine metabolism in cells exposed to glucose-
containing medium and treated with 2 and 5 mM of 
metformin. B. Relative mRNA expression levels in Caco2 
cells seeded in the presence or absence of glucose 
(GLN/GLN+GLU). C. Gene expression levels of Caco2 
grown in the absence of glucose treated with 2 and 5 
mM of metformin. Data are expressed as means ± SEM 
and differences between groups were assessed by the 
unpaired t-test or ANOVA; *p < 0.05, **p < 0.01.
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in regulating glutamine metabolism was also assessed. PCS 
animals show hyperammonemia, alterations of circadian 
rhythms, different aromatic/branched chain amino acid 
ratios, decreased brain glucose utilization, oxidative/nitro-
sative stress and an interrupted function of multiple neu-
rotransmitters similar to HE in human cirrhotic patients (25). 
Although circulating levels of ammonia depend on the 
action of various organs, this study was focused on KGA. 
The activity of this enzyme in the duodenum has been pro-
posed as the main source of the neurotoxin related to the 
presence of HE and the degree of hepatic dysfunction in 
patients with cirrhosis (6,26). Besides, higher concentra-
tions of metformin were found in the small intestine com-
pared to other tissues or in plasma (up to about 500 mg/g 
of tissue). This raises the possibility that the small intestine 
might be a significant site of action of the drug (27). We pre-
viously showed that the increase in ammonia was related 
to an increased activity of the glutaminase enzyme in the 
gut of PCS rats. This is consistent with the concept that gut 
ammonia production is increased in cirrhotic patients after 
oral glutamine challenge (6,19). In this study, our results 
indicate that metformin treatment resulted in a reduction 
of ammonia production reflected by a decrease in glutam-
inase activity, which was directly measured in plasma and 
cell culture supernatant. However, this study has some lim-
itations, largely related to its proof-of-concept design. The 
absence of statistical significance in some points might be 
due to the low sample size in the in vivo study. Besides, the 
in vitro study may be performed in more than one cell line. 
Nevertheless, our data seem to corroborate the influence 
of this drug on ammonia homeostasis, postulating it as 
an alternative therapy against HE. The fact that no chang-
es were found in glutaminase gene expression suggests 
a posttranscriptional effect, as proposed previously (28). 
In accordance with our data, Jover-Cobos et al. showed a 
reduction in glutaminase activity in the gut after treatment 
with ornithine phenylacetate in bile-duct ligated rats (29). 
However, since this study was conceived as a proof of con-
cept, further studies with a larger sample size are needed. 
Several compounds have recently been tested that inhibit 
KGA such as DON (6-diazo-5-oxy-i-norleucine), an unspecif-
ic glutamine-competitive irreversible KGA inhibitor, which 
is the most commonly used (30). Other molecules such as 
968, BPTES or THDP17 have also been reported to inhibit 
glutaminase via different mechanisms with in vitro efficacy. 
However, despite all efforts, its high in vivo toxicity means 
it cannot be used for treatment (31,32). Nevertheless, these 
studies suggest the possibility of many other scaffolds that 
inhibit glutaminase enzyme activity, enabling further inves-
tigations in the field. 
Recently, it has become clear that overexpression of MYC 
causes glutamine addiction via a coordinated transcrip-
tional program by the stimulation of glutamine uptake and 
metabolism, both directly and indirectly. MYC directly binds 
to the promoters and stimulates the expression of genes 
involved in glutaminolysis, such as the transporter ASCT2 
and several enzymes utilizing glutamine (8). MYC also influ-
ences post-transcriptional regulation, as its overexpression 
correlates with a significant upregulation of glutaminase 
protein levels. This occurs indirectly by repression of the 
expression of miR-23a/b, which target GLS in the 3’ untrans-
lated region (UTR) (33). 
Here, we confirmed that glucose deprivation induces an 
overexpression of SLC1A5 leading to increased glutamine 
uptake, in order to sustain ATP generation through the TCA 
cycle. In fact, glutamine could sustain the oxidative TCA 
cycle in MYC-driven cells, even in a glucose deprivation 
environment, and cells would undergo apoptosis in the 
absence of this amino acid (34).
A further role for glutamine in cell protein translation stems 
from observations that a master regulator of protein trans-
lation, the mammalian target of rapamycin complex 1 
(mTORC1), is responsive to glutamine levels (35). MYC and 
mTOR are involved in a positive feedback loop. mTORC1/
S6K1 controls MYC expression by modulating mRNA 
translation initiation efficiency via phosphorylation of the 
initiation factor eIF4B. On the other hand, MYC promotes 
mTORC1 activity by facilitating leucine uptake (36). The 
study of Fuchs et al. in 2007 showed that silencing ASCT2 
in hepatoma cells caused a reduction of mTOR activity lead-
ing to apoptosis. Glutamine taken up by ASCT2 stimulates 
leucine uptake by a parallel leucine/glutamine antiport cat-
alyzed by the large neutral amino acid transporter 1 (LAT1), 
this promotes mTORC1 assembly and lysosomal localiza-
tion (37,38). Furthermore, rapamycin decreases ASCT2 
expression, thus indicating a reciprocal effect between this 
transporter and mTOR activity (37).
Our results show a feedback between MYC and mTOR 
under glucose withdrawal and ratify its role in the regu-
lation of glutamine metabolism via ASCT2 and KGA. Met-
formin treatment caused a downregulation of both MYC 
and mTOR, as previously demonstrated (39,40). In addition, 
a study by Akinyeke et al. in 2013 showed that the drug 
stimulates cell cycle arrest and apoptosis with a reduc-
tion of MYC protein levels by at least 50% in vitro and in 
vivo (41). They addressed the effects on the AMP-activat-
ed kinase (AMPK) pathway. However, a recent report sug-
gested that MYC deregulation was a direct consequence of 
metformin-mediated upregulation of miR-33a/b, an intronic 
miRNA located within the sterol regulatory binding protein 
(SREBPs) genes (42).
Along these lines, we suggest that an increased use of 
glutamine as a carbon source for the cells, the greater the 
impact that metformin would have on them. Increased glu-
taminolysis was reported to be induced by a high α-keto-
glutarate/citrate ratio. Stress and hyperammonemia have 
been described to inhibit α-ketoglutarate dehydrogenase, 
which catalyzes decarboxylation of α-ketoglutarate in the 
TCA cycle. This increases the ratio and triggers enhanced 
glutaminolysis (43). The MYC oncogene controls the glu-
taminolytic pathway and induces glutamine addiction. 
Metformin use would reduce MYC levels in these cells and 
therefore, ASCT2 and KGA. This would result in a reduc-
tion in the production of metabolites and energy through 
this pathway and as an indirect consequence, a decrease in 
ammonia production that could be related to a decreased 
risk of HE development.
In conclusion, our findings lead us to hypothesize that the 
reduction of hyperammonemia in PCS rats caused by met-
formin treatment could be explained by a slight modulation 
of glutaminase activity. Besides, in vitro glucose withdrawal 
enhances the expression of genes involved in glutamine 
metabolism, which confers sensitivity to metformin by 
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decreasing both absorption and degradation of this amino 
acid in the enterocyte. This could explain, at least in part, 
the lower prevalence of HE in patients taking metformin. 
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